SOURCE: Syneron Medical Ltd.

Syneron Medical Ltd.

November 15, 2011 07:00 ET

Syneron Implements Industry First Breakthrough: Extended-Time Accessories to Optimize Customers' Return on Investment

VelaShape® II New Eight-Hour Covers and eTwo™'s Sublative iD™ Tips Both Feature Extended-Time Maximizing Productivity and Profitability for Loyal Customers

YOKNEAM, ISRAEL--(Marketwire - Nov 15, 2011) - Syneron Medical Ltd. (NASDAQ: ELOS),, the global leader in medical aesthetic products and technology announces the release of extended-time accessories that dramatically improves the productivity and profitability of the VelaShape II and recently introduced eTwo platform. "We've been very fortunate to develop a strong and loyal following across all continents over the past decade," said Louis P. Scafuri, Chief Executive Officer of Syneron Medical. "The voice of our customers seeks innovation, driven by results, to respond to the ever-changing market conditions. As a result we're delighted to offer the industry's first modification that supports our loyal customers and ensures their return on investment with two of our most in demand products."

The new eight-hour covers, only available on VelaShape II, now allows practitioners eight times more productivity from a single cover -- a substantial improvement from the original one-hour covers. On average a VelaShape treatment ranges from 20 to 30 minutes for one area, with 4 to 6 treatments to complete the series. "I view this as a significant commitment by the company to help support my practice and the bottom line of our VelaShape business," said Alan Gold, M.D., board certified Plastic Surgeon in Great Neck, New York. "Our patients want proven, safe and effective technologies and that's what Syneron delivers -- not flashy marketing promises without the ability to produce the promised results. Syneron's extended-time accessories are yet another example of their proactive approach to continually improve even their established technologies and provide their customers with the most practical and cost-effective treatment options for our patients."

The new Sublative iD tips now allow practitioners a re-connectable solution to further maximize their Sublative™ treatments -- another substantial improvement from the original one-time use tips. Practitioners now have the freedom to disconnect the tip and resume treatments while maximizing pulses when necessary. "As a practitioner I chose to invest in both these products because of my long-standing trust in the company's technologies," said Vince Afsahi, M.D., board certified Dermatologist and Medical Director at South Coast Dermatology Institutes in Newport Beach and Tustin, California. "But as a business owner it's refreshing to have a business partner that understands the needs of my practice and patients and works with us to competitively price these technologies in the forefront of my practice."

Both cover and tip are available to current customers on For more information about VelaShape II and eTwo visit

About VelaShape® II
Powered by Syneron's proprietary elos™ technology, VelaShape II works to effectively treat both the upper to deep tissue of the skin offering measurable reduction in circumference and the appearance of cellulite. With over 750 millions media impressions and growing, VelaShape II remains the popular choice for non-surgical and non-invasive approach to cellulite and body contouring.

About eTwo
The eTwo platform, along with its Sublime™ and Sublative™ applications received FDA cleared and CE mark for dermatological procedures requiring ablation and resurfacing in addition to non-invasive wrinkle treatment in Fall 2011. eTwo pairs Syneron's proprietary elos® technology with Syneron's globally successful Sublative application for a complete solution to facial rejuvenation

About Syneron Medical Ltd.
Syneron Medical Ltd. -- a company devoted to real technology, real science and real results -- is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. The Company's aspiration and commitment to innovation expands Syneron's offering beyond medical device into the largest in-demand applications in beauty -- skin lightening. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide. Additional information can be found at

Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that the merger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements. In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.

Contact Information

  • Contacts:
    Syneron - Public Relations
    Email Contact

    Asaf Alperovitz
    Chief Financial Officer
    + 972 73 244 2283

    Zack Kubow
    The Ruth Group